Chugai Pharmaceutical Co., Ltd. (Japan)
1-9, Kyobashi 2-chome
107 articles with Chugai Pharmaceutical Co., Ltd. (Japan)
New Data of Chugai’s Enspryng (Satralizumab) on Risk and Severity of Relapse in Neuromyelitis Optica Spectrum Disorder (NMOSD)
Chugai Pharmaceutical Co., Ltd. announced the presentation of new Enspryng® data on reducing relapse severity in the treatment of neuromyelitis optica spectrum disorder, a rare disease of the central nervous system.
Chugai’s Enspryng (Satralizumab) Receives Regulatory Approval from FDA for Neuromyelitis Optica Spectrum Disorder
A treatment option with a novel mechanism of action for anti-aquaporin-4 seropositive neuromyelitis optica spectrum disorder (NMOSD) approved in the U.S.
- Chugai and Biofourmis are partnering to develop a digital solution leveraging Biofourmis' Biovitals® platform for pain management in patients with endometriosis - A non-interventional study will be conducted with endometriosis patients to validate the novel tool in real-life conditions
Positive Results from the Second Phase III SAkuraStar Study for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) Published in The Lancet Neurology
Satralizumab monotherapy significantly reduced risk of relapse in patients with NMOSD, following a previous positive study where satralizumab was added to baseline immunosuppressant therapy.
Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766
Combination of Defactinib and CH5126766 Shows Promise in Treating KRAS Mutant Solid Tumors in Clinical Trial
EMA and FDA Accept Marketing Applications for Chugai's Satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
NMOSD is a rare disease where repeated relapses may result in visual impairment and motor disability in the course of disease progression.
Chugai Presents Results from Second Positive Global Phase III Clinical Study of Satralizumab in NMOSD at ECTRIMS 2019
Chugai Pharmaceutical Co., Ltd. announced that the results from SAkuraStar Study were presented at the Congress of European Committee for Treatment and Research in Multiple Sclerosis 2019.
Final Progression-Free Survival Data and the Second Interim Analysis of Overall Survival from the J-ALEX Study for Alecensa Presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Chugai Pharmaceutical Co., Ltd. announced that the final progression-free survival data and the second interim analysis of overall survival from the Japanese phase III J-ALEX study for Alecensa® were presented on June 2 at the 2019 American Society of Clinical Oncology Annual Meeting, taking place from May 31 to June 4 in Chicago, IL, United States.
Chugai’s Hemlibra Receives Approval for Severe Hemophilia A Without Factor VIII Inhibitors from the European Commission
Chugai Pharmaceutical Co., Ltd. announced that Roche received the decision from the European Commission confirming that Hemlibra® has EU marketing authorization for routine prophylaxis of bleeding episodes in adults and children with severe hemophilia A (congenital factor VIII deficiency, FVIII <1%) without factor VIII inhibitors.
The collaboration between Chugai and Rosa will provide Chugai a competitive research and development advantage across multiple therapeutic areas and throughout Chugai's R&D pipeline, delivering unique scientific insights and actionable program recommendations, reducing risk and addressing complex and consequential decisions inherent in drug development.
Chugai Pharmaceutical Co., Ltd. announced that Roche has joined the World Federation of Hemophilia Humanitarian Aid Program.
Chugai Pharmaceutical Co., Ltd. announced that Roche has received notification that the EU Committee for Medicinal Products for Human Use adopted a positive opinion for Hemlibra®
With the holiday upon us, many companies in the pharma and biotech industry have made some important announcements – some big, some small. BioSpace has gathered a number of announcements that might have gone unnoticed and put them together below.
Satralizumab monotherapy significantly reduced risk of relapse
Chugai's Satralizumab Receives FDA Breakthrough Therapy Designation for Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
－Designation is Seventh for Chugai Originated Drug－
Results Presented from Primary Analysis of the Phase III HAVEN 2 Study with Chugai's HEMLIBRA® for Children with Hemophilia A with Inhibitors at the American Society of Hematology 2018
Chugai Pharmaceutical Co., Ltd. announced that the primary analysis of the phase III HAVEN 2 study (NCT02795767), evaluating hemophilia A treatment HEMLIBRA® in children with hemophilia A with factor VIII inhibitors, was reported in an Oral Presentation at the 60th American Society of Hematology (ASH) Annual Meeting held in San Diego, USA from December 1 to 4 2018.
Indianapolis-based Eli Lilly announced that its diabetes drug Trulicity (dulaglutide) reduced major adverse cardiovascular events (MACE) in its REWIND clinical trial.
Anaeropharma Science Signs Collaborative Research Agreement with Chugai on Creation of Novel Oncology Drugs Using Bifidobacterium
Anaeropharma Science Inc. announced on October 22 that Anaeropharma Science and Chugai Pharmaceutical Co., Ltd. headquartered in Tokyo (hereinafter "Chugai") have concluded a collaborative research agreement concerning the creation of novel oncology drugs utilizing characteristic features of Bifidobacterium longum through Anaeropharma's proprietary platform technology, "in situ Delivery and Production System" (hereinafter "i-DPS").
Satralizumab added to baseline therapy significantly reduced risk of relapse
Chugai Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved HEMLIBRA® (US generic name: emicizumab-kxwh), a treatment for hemophilia A created by Chugai, for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A without factor VIII inhibitors, administered once weekly, every two weeks, or every four weeks.